TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases

Chi Young Ok(The University of Texas MD Anderson Cancer Center), Sa A. Wang(The University of Texas MD Anderson Cancer Center), Ken H. Young(The University of Texas MD Anderson Cancer Center), Mark J. Routbort(The University of Texas MD Anderson Cancer Center), Guilin Tang(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Maitrayee Goswami(The University of Texas MD Anderson Cancer Center), Rajyalakshmi Luthra, Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Jie Peng(The University of Texas MD Anderson Cancer Center), L. Jeffrey Medeiros(The University of Texas MD Anderson Cancer Center), Rajesh R. Singh(The University of Texas MD Anderson Cancer Center), Keyur P. Patel(The University of Texas MD Anderson Cancer Center)
Journal of Hematology & Oncology
May 7, 2015
10.1186/s13045-015-0139-z
Cited by 142

Related Papers

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
|Blood|2017|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
|Blood|1997|1.2k